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Mesencephalic astrocyte-derived neurotrophic factor (MANF), a newly discovered
secreted neurotrophic factor, has been proven to not only protect dopaminergic neurons
and other cell types but also regulate neuroinflammation and the immune response
to promote tissue repair and regeneration. However, to date, there is no information
regarding the relationship between MANF and retinal ganglion cells (RGCs) in the eye. In
the current study, we first determined the expression of MANF in the retina and vitreous.
Then, we examined the effect of MANF on RGCs using both in vivo and in vitro models
and simultaneously explored the underlying neuroprotective mechanisms of MANF.
Finally, we measured the concentrations of MANF in the vitreous of patients with different
retinopathies. We demonstrated that MANF was highly expressed in RGCs and that
exogenous MANF could protect RGCs from hypoxia-induced cell injury and apoptosis
both in vitro and in vivo by preventing endoplasmic reticulum stress-mediated apoptosis.
Furthermore, MANF can be detected in the vitreous humor, and the concentration
changed under pathological conditions. Our results provide important evidence that
MANF may be a potential therapeutic protein for a range of retinal pathologies in either
the preclinical stage or after diagnosis to promote the survival of RGCs. Vitreous MANF
may be a promising protein biomarker for the indirect assessment of retinal disorders,
which could provide indirect evidence of retinal pathology.
Keywords: mesencephalic astrocyte-derived neurotrophic factor, retinal ganglion cells, neuroprotective,
endoplasmic reticulum stress, retinal pathology
INTRODUCTION
Mesencephalic astrocyte-derived neurotrophic factor (MANF), also known as Armet, was first
isolated from a rat type-1 astrocyte ventral mesencephalic cell line. MANF is widely expressed in
the nervous system and non-neuronal tissue, such as the cerebral cortex, liver, and heart (Lindholm
et al., 2008). Because MANF is a secreted protein, its expression is especially abundant in secretory
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cells and tissues, including human serum, salivary glands,
and embryonic pancreas. Recently, studies conducted at the
University of Helsinki demonstrated that the concentration
of MANF is increased in the serum in children with type
1 diabetes, which indicated that MANF may be used as a
potential therapeutic protein for diabetes (Galli et al., 2016).
Furthermore, our recent studies showed that MANF could be
robustly expressed in RGCs and that hypoxia can stimulate the
up-regulation of MANF expression over time, which suggested
that MANF may play a vital role in the functional regulation of
RGCs in both health and disease (Gao et al., 2017).
Recent advances have indicated that MANF could protect
dopaminergic neurons and cell types in animal models of
Parkinson’s disease, Alzheimer’s disease, and brain ataxia
(Petrova et al., 2003; Lindholm et al., 2007). MANF is a new
secretory neurotrophic factor, and its expression and secretion
are regulated by endoplasmic reticulum stress (ERS) (Apostolou
et al., 2008; Tadimalla et al., 2008). MANF not only modifies
ER homeostasis to protect cells against ERS-induced cell death
but also regulates neuroinflammation and the immune response
to promote tissue repair and regeneration (Neves et al., 2016;
Zhu et al., 2016). The mechanisms of the neuroprotective
effects of MANF in rodent models of cerebral ischemia and
spinocerebellar ataxia are mediated by inhibition of ischemia-
induced apoptosis (Yang et al., 2014). Numerous eye diseases
are associated with neuronal apoptosis, ERS, inflammation, and
ischemia, such as diabetic retinopathy (Ikesugi et al., 2006;
Li et al., 2009; Tang and Kern, 2011; Zhang et al., 2015),
glaucomatous optic neuropathy (Yang et al., 2011; Ha et al., 2015),
retinal detachment (Liu et al., 2010; Zhu et al., 2013), and age-
related macular degeneration (Li et al., 2008; Libby and Gould,
2010). These findings suggest that MANF may be a promising
therapeutic strategy for promoting the survival of retinal neurons.
Therefore, we hypothesized that MANF may have therapeutic
potential for the treatment of retinopathy. However, there is little
research available on this subject. The only study on MANF
in the retina was reported in Science and demonstrated for the
first time that MANF is expressed in the mouse retina and
exerts immune modulatory function to promote tissue repair
and successful regeneration in the retina (Neves et al., 2016).
These results provided a strong foundation for our current
study and revealed that further attention and investigation of
the expression, function, and effect of MANF in retinopathy are
imperative.
In the current study, we first determined the expression
of MANF in the retina and vitreous. Then, we assessed the
effect of MANF on retinal ganglion cells (RGCs) using both
in vivo and in vitro models and simultaneously explored the
underlying neuroprotective mechanisms. Finally, we measured
the concentrations of MANF in the vitreous of patients with
different retinopathies. We demonstrated that MANF was
highly expressed in the RGCs and that exogenous MANF
could protect RGCs from hypoxia-induced cell injury and
apoptosis both in vitro and in vivo by preventing ERS-mediated
apoptosis. MANF can be detected in the vitreous humor,
and the concentration of MANF changed under pathological
conditions.
MATERIALS AND METHODS
Animals and Ethics Statement
A total of 92 male Sprague-Dawley rats (150–200 g ) and 150
newborn Sprague-Dawley rats (1–4 days) (SLAC Laboratory
Animal Co., Ltd. Shanghai, China) were used. This study was
carried out in accordance with the guidelines of Shanghai
Jiaotong University Affiliated Sixth People’s on the ethical use
of animals. The protocol was reviewed and approved by the
animal experimental ethics committee of Shanghai Jiaotong
University Affiliated Sixth People’s. The animal handling and
experimental protocols were carried out in accordance with
the approved guidelines of Animal Care and Use Committee
of Research Ethical Committee, Shanghai Jiaotong University
Affiliated Sixth People’s and the Association Research in Vision
and Ophthalmology (ARVO) Statement for the Use of Animals in
Ophthalmic and Vision Research. Animals were kept in standard
cages at room temperature (15–25◦C) and 12-h light/12-h dark
schedule with food and water available ad libitum.
Sprague-Dawley rats were allocated randomly into normal
control (NC) group (n = 26), chronic ocular hypertension
(COHT) group (n = 32), COHT + PBS group (n = 8,
intravitreous injection of 2 µl PBS) and COHT + MANF group
(n = 26, intravitreous injection of 2 µl, 1 µg/ml). In this study,
all animals were anesthetized by intraperitoneal injection of 10%
chloral hydrate.
Patients and Vitreous Samples and
Ethics Statement
In this study, vitreous samples were obtained from 55 patients
undergoing vitreoretinal surgery, including 21 proliferative
diabetic retinopathy, 16 retinal detachment and 18 macular
hole patients. The mean age was 48.71 ± 11.83 years (range
29–65 years). This study was carried out in accordance with
the recommendations of Shanghai Jiaotong University Affiliated
Sixth People’s Hospital with written informed consent from
all subjects. All subjects gave written informed consent in
accordance with the Declaration of Helsinki. The protocol was
approved by the Office of Research Ethical Committee, Shanghai
Jiaotong University Affiliated Sixth People’s Hospital. Undiluted
vitreous samples were obtained at the onset of vitrectomy and
frozen at −80◦C immediately until assayed. Healthy vitreous
was obtained from the Shanghai Jiaotong University Affiliated
Sixth People’s Hospital following the guidelines of the Shanghai
Jiaotong University Clinical Human Research Ethics Committee
(n = 2). Both were from donors who had been screened to make
sure there was no underlying ocular disease.
Cell Culture and Treatment
Primary cultured RGCs were purified by two-step
immunopanning method as we described previously (Gao
et al., 2016). RGCs were collected and seeded into 96, 24 and
6-well plates pretreated with mouse-laminin (Trevigen Inc.,
Gaithersburg, MD, USA) and poly-D-lysine (Sigma–Aldrich,
St. Louis, MO, USA). Plates were incubated in a humidified
incubator with 5% CO2 at 37◦ C. RGCs purity was checked by
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Thy1.1 and Brn 3b immunocytochemical staining (about 85%)
(Gao et al., 2016). Forty-eight hours after seeding, RGCs were
incubated with 200 µM cobalt chloride (CoCl2, Sigma–Aldrich,
St. Louis, MO, USA) to induce hypoxia and apoptosis (Kim et al.,
2013), combined with 0, 10, 20, 50, or 100 ng/ml MANF for 24 h,
then incubated 12 h, 24 and 48 h under optimal concentration.
Half of the RGC medium was replaced with fresh RGC medium
every 3 days.
Intraocular Pressure (IOP) Elevation and
MANF Treatment
Elevation of IOP was induced by injection of 5µl of paramagnetic
polystyrene microbeads (FluoSpheres; Invitrogen, Carlsbad, CA,
USA; 15-µm diameter) into the anterior chamber of the right
eye of each animal under a surgical microscope, as previously
reported (Sappington et al., 2010). IOP was measured every
3 days after the injection using a rebound tonometer (Icare R©
Tonolab, TioLat, Helsinki, Finland). All the measurements were
performed between 9 and 10 am by the same operator, and the
IOP is reported as the mean ± standard deviation (SD) of the
average of three independent readings.
A dose of 2 µl of MANF (1 µg/ml, PeproTech, Rocky Hill, NJ,
USA) was intravitreally injected 2 days before increased IOP was
induced and then once a week for 2 weeks.
Immunofluorescence
Immunofluorescence staining was conducted as previously
described Wu et al. (2013). The eyes and RGCs from different
groups were fixed with 4% paraformaldehyde (PFA) for
2 h and 20 min at room temperature, respectively. Then,
the eyes were cut into 8-µm-thick sections after graded
dehydration with 20 and 30% sucrose solution and then
stored at −80◦C until use. Sections and RGCs were incubated
in 0.1% Triton X-100 and 3% (w/v) bovine serum albumin
(BSA) (Sigma–Aldrich, St. Louis, MO, USA) for 30 min
sequentially at room temperature to prevent non-specific
background. Then, sections and RGCs were incubated with
rabbit anti-MANF (1:200, Abcam, Cambridge, MA, USA) and
anti-survivin (1:200, Abcam, Cambridge, MA, USA) antibody
at 4◦C overnight, followed by successive incubations with
fluorescein-conjugated goat anti-rabbit secondary antibody
(1:400, Molecular Probes, USA) and Hoechst staining.
Negative controls were routinely prepared by incubating
the cells and retinal sections in normal buffered serum
instead of the primary antibody. The stained sections and
cells were visualized and imaged using confocal microscopy
(Leica SP8, Hamburg, Germany).
Cell Counting Kit-8 (CCK8) Assay for
RGC Viability
CCK8 solution (Dojindo Laboratories, Kumamoto, Japan) was
added to 96-well plates (10 µl/well). After a 4-h incubation at
37◦C, the plates were analyzed at 450 nm with the Tecan Genios
microplate reader (Synergy H1, BioTAK). All values are expressed
as the mean± SD of at least three wells and at least three separate
experiments. As the initial cell density was the same, higher OD
values represent increased cell viability over time. We compared
the changes in the OD values at different times to evaluate the
RGC viability.
Caspase 3/7 Activity
Approximately 10,000 purified RGCs were seeded into 96-well
plates. The caspase 3/7 activation in the different groups was
evaluated by the Caspase-Glo 3/7 assay (Promega, Milano, Italy),
as previously reported Park et al. (2016). The luminescence
signals from the cell lysate solution were determined with the
Tecan Genios microplate reader (Synergy H1, BioTAK). All
experiments were performed in triplicate.
Flow Cytometry Analysis of Apoptosis
The proportion of apoptotic cells was measured using a
FACSCalibur platform according to the manufacturer’s
instructions for the Annexin V-FITC/PI flow cytometric
assay kit (Becton Dickinson, San Jose, CA, USA). Briefly,
after each treatment, the cells were collected, washed,
and resuspended in phosphate-buffered saline (PBS)
containing Annexin V-FITC and PI for 20 min in the
dark at 37◦C in 5% CO2. Then, the stained cells were
analyzed using a FACSCalibur platform. The percentage of
apoptotic cells was determined by calculating the number
of annexin V+/PI-cells. All experiments were performed in
triplicate.
Western Blot Analysis
To obtain a high protein concentration from the vitreous
samples for Western blot analysis, protein precipitation
must be the first step. In the current study, the vitreous
was concentrated using the acetone method as described
by Jiang et al. (2004). Primary cultured RGCs and retinal
protein extractions were performed as previously described
Wu et al. (2015). Then, the protein concentration was
quantified using a BCA protein assay kit (Thermo Fisher
Scientific, Rockford, IL, USA); the proteins were separated
by SDS-polyacrylamide gel electrophoresis; and the separated
proteins were electrotransferred to polyvinylidene difluoride
membranes. After blocking with 5% non-fat milk for 30 min,
the membranes were incubated overnight at 4◦C with primary
antibodies against MANF, survivin, ERS-associated protein
CCAAT-enhancer-binding protein (C/EBP), homologous
protein (CHOP), cleaved caspase-3 antibody, and β-actin
(Abcam, Cambridge, MA, USA). The secondary antibodies
included HRP-conjugated goat anti-rabbit antibody (Millipore,
Billerica, MA, USA) and HRP-conjugated goat anti-mouse
antibody (Millipore, Billerica, MA, USA). The Western blots
were imaged with the Kodak Imaging System (Kodak 440CF)
using the ECL Western blotting substrate (Hyperfilm ECL,
Thermo Fisher Scientific, Rockford, IL, USA). The intensity of
the band was quantified by densitometry using ImageJ software
(NIH, Bethesda, MD, USA).
TUNEL Assay
TUNEL staining was performed according to the manufacturer’s
instructions (In Situ Cell Detection Kit; Roche, Mannheim,
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FIGURE 1 | Immunofluorescence staining of MANF protein in rat cultured RGCs (C), human retina (A), and Sprague-Dawley rat retina (B). MANF staining
was mainly distributed throughout the GCL, with some labeling in the INL (indicated by arrowheads). The nuclei were labeled with DAPI (blue). Magnification 400X;
Scale bar: 50 µm. ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer.
Germany) as we previously reported Fu et al. (2016). Cultured
RGCs were fixed in 4% (w/v) PFA at 4◦C for 30 min and
then blocked with 3% BSA and 0.1% Triton X-100 for 1 h at
room temperature. The TUNEL reaction mixture was added to
the samples and incubated for 60 min at 37◦C in the dark.
After 3 rinses with PBS, the samples were stained with DAPI
(1:2000; Life Technologies, Molecular Probes, NucBlue Fixed Cell
Stain, Eugene OR, USA). The TUNEL-positive cell nuclei were
visualized using a confocal microscope (Leica SP8, Hamburg,
Germany) and quantified using ImageJ software. Six microscope
fields of view from six different wells were analyzed per treatment
condition.
Photopic Negative Response (PhNR)
Recordings
The PhNR was recorded to evaluate RGC function at baseline and
after 3, 7, and 14 days of IOP elevation as previously reported
Rangaswamy et al. (2007) and Porciatti (2015). After the rats
were anesthetized, the pupils were dilated with phenylephrine
hydrochloride and tropicamide, and two 3-mm platinum wire
loop electrodes were then placed on the corneal surface of the
eyes. One subdermal needle electrode inserted at the base of
the right leg served as the ground, and the other subdermal
needle electrode placed over the nasal bone acted as the common
reference. Light stimuli were delivered using a ColorDome unit.
Four different stimuli of 11.38 cd.s/m2-0.33 Hz, 11.38 cd.s/m2-
1 Hz, 22.76 cd.s/m2-0.33 Hz, and 22.76 cd.s/m2-0.33 Hz were
used in a four-step examination. In each step, the stimulus
frequency was 2 Hz, with a 4-ms exposure to a green light on a
green background with an intensity of 10 cd/m2 displayed by the
Espion Visual Electrophysiology System (Espion E3, Diagnosys,
Diagnosys UK Ltd, UK). The PhNR amplitude was recorded from
the baseline to the trough of the negative response.
Retrograde Labeling and Counting of
RGCs
The procedures were performed as previously reported (Wu et al.,
2013). Briefly, Fluoro-Gold (FG, Sigma–Aldrich, St. Louis, MO,
USA) was injected into the superior colliculus on each side after
the rats in each of the four groups were deeply anesthetized. One
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FIGURE 2 | (A) The viability of RGCs treated with 0–100 ng/ml MANF with or without CoCl2 was measured by the CCK-8 assay. The bars represent the
means ± SD, ∗p < 0.05, ∗∗p < 0.01. (B) The viability of RGCs treated with 50 ng/ml MANF and 200 µM CoCl2 for 0, 12, 24, and 48 h. The bars represent the
means ± SD. ∗p < 0.05, ∗∗p < 0.01. (C) Caspase 3/7 activities were measured by a luciferase assay. The bars represent the means ± SD. ∗∗p < 0.01. (D)
Apoptosis was detected by Annexin V and propidium iodide (PI) staining in RGCs treated with 50 ng/ml MANF and 200 µM CoCl2 for 24 h. The R4 quadrant
(Annexin V-/PI-), R5 quadrant (Annexin V+/PI−), and R3 quadrant (Annexin V+/PI+) indicate the percentage of viable cells, apoptotic cells, and necrotic cells,
respectively. (E) The percentage of apoptotic cells following CoCl2 treatment with or without MANF. The values represent the mean ± SD of three independent
experiments. ∗∗p < 0.01.
week post-injection, the rat eyes were harvested and placed in 4%
PFA for 2 h at room temperature, and the whole retina was then
carefully dissected and flat-mounted on a slide. The RGCs were
counted and averaged per eight microscopic fields of identical size
at a distance of 1–2 mm from the optic nerve head where the RGC
densities were comparable at 200 × magnification. Each group
contained at least three rats for measurement of the mean density.
The RGCs were manually counted by two operators in a blinded
manner using ImageJ software (NIH, Bethesda, MD, USA). The
density of RGCs is expressed as the number of cells per mm2.
Enzyme-Linked Immunosorbent Assay
(ELISA)
The levels of vitreous MANF expression were measured
by human ELISA kits (CUSBIO Life Science, College Park,
MD, USA) according to the manufacturer’s instructions.
The vitreous samples were diluted 10 times before analysis.
The acceptance criteria of the assay followed the previously
published recommendations (DeSilva et al., 2003). The MANF
concentration was calculated from the standard curve of six
individual assays.
Statistical Analysis
All data are expressed as the means ± SD and were analyzed
using SigmaStat software. All data were assessed by the Shapiro–
Wilk test, and only variables that were normally distributed were
tested; we also analyzed the variance of the data, followed by
performance of the two-tailed unpaired Student’s test. Values
of p < 0.05 were considered the threshold for statistical
significance.
RESULTS
Expression and Distribution of MANF in
the Normal Rat Retina
As we have previously described Gao et al. (2017),
immunofluorescence staining shows that MANF is
predominantly localized in the ganglion cell layer and inner
nuclear layer in both rat and human retinas (Figures 1A,B).
To determine if the MANF expression in the ganglion cell
layer was specific to the RGCs, primary cultured RGCs were
used for in vitro validation. The results confirmed that MANF
was robustly expressed in the RGC somas (Figure 1C). These
observations suggest that MANF may play a potential role in the
pathophysiology of the retina, especially of the RGCs.
MANF Prevents Hypoxia-Induced RGC
Apoptosis
To determine whether MANF exerts neuroprotective effects
on the RGCs, primary RGCs were cultured under hypoxia
with or without exogenous MANF. We found that CoCl2
significantly inhibited cell viability (OD value:0.548 ± 0.086
vs. 0.438 ± 0.078, n = 9, p < 0.01, Figures 2A,B), while
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FIGURE 3 | (A) TUNEL analysis of RGCs from three different groups: NC
group, CoCl2 treatment group (24 h), and CoCl2 with MANF treatment group
(24 h). Red indicates TUNEL-positive cells, and blue indicates DAPI. All
images were captured at the same magnification. Scale bar, 50 µm.
(B) Quantitative analysis of TUNEL-positive cells in the different treatment
groups. The data are presented as the means ± SD. ∗∗∗p < 0.001, the
hypoxia group compared with the NC group; ∗∗p < 0.01, the
hypoxia + MANF group compared with the hypoxia group.
MANF rescued cell viability in a dose- and time-dependent
manner in the RGCs treated with CoCl2. Because cell viability
reached the optimum level at 50 ng/ml for 24 h (OD
value:0.576 ± 0.069, p = 0.0081, <0.01, Figures 2A,B), we used
50 ng/ml as the optimal effective concentration in subsequent
studies.
Furthermore, the protective effect of MANF was evaluated
by measuring the caspase 3/7 activity using a luminescent
caspase activity assay kit (Figure 2C). Caspase 3/7 activity
was significantly increased under hypoxia (1.45 ± 0.48-fold,
p = 0.0069, <0.01), whereas MANF treatment remarkably
decreased caspase 3/7 activity by 0.65 ± 0.16-fold compared
with the hypoxia group (p = 0.0076, <0.01). These results
suggested that MANF could inhibit CoCl2-induced caspase 3/7
activation. RGC apoptosis and death were also evaluated by
the flow cytometry-based Annexin V + PI assay and TUNEL
staining. As shown in Figures 2D,E, 3, the numbers of annexin
V (+) and TUNEL-positive RGCs were significantly increased
under hypoxia (4.69 ± 0.78-fold, p < 0.01 vs. 5.98 ± 1.05-
fold, p< 0.001), whereas MANF treatment remarkably decreased
the number of apoptotic RGCs (decreased by 0.57 ± 0.12-
fold, p < 0.01 vs. 0.48 ± 0.11-fold, p < 0.01). These results
collectively demonstrated that MANF can protect RGCs from
hypoxia-induced apoptosis in vitro.
Mechanisms of the Protective Effect of
MANF on RGCs
For a further in-depth exploration of the mechanisms of
the protective effect of MANF on RGCs under hypoxia, the
levels of the anti-apoptotic survivin, apoptosis-related cleaved
caspase-3, CHOP, and MANF proteins were analyzed by
Western blotting (Figure 4). The results demonstrated that
the expression levels of survivin were reduced (p = 0.0092,
<0.01), while the levels of cleaved caspase-3, the activated
form of caspase-3, were significantly upregulated (p = 0.0077,
<0.01) after 24 h of CoCl2 treatment (Figures 4A,B). However,
these changes were remarkably reversed by MANF treatment
(p = 0.0056, <0.01). CHOP, a pro-apoptotic factor, was
increased by >1.39 ± 0.12-fold and 1.49 ± 0.22-fold after
12 and 24 h of CoCl2 treatment, respectively, compared
with the NC group, whereas MANF treatment markedly
inhibited CHOP expression. Meanwhile, the expression levels
of MANF were changed in a similar manner to CHOP
(Figures 4C,D). These data indicated that MANF could protect
against hypoxia-induced RGC apoptosis by upregulating the
expression levels of survivin and suppressing the levels of cleaved
caspase-3 and CHOP.
Induction of Experimental Glaucoma
To validate the protective effects of MANF on the RGCs, in vivo
studies are needed. In the current study, a rat COHT model was
used to establish the hypoxic injury to the RGCs. As shown in
Figure 5A, significant IOP elevation (defined as 5 mmHg greater
than the contralateral eye) was observed on the first day after the
microbead injection (21.96± 3.64 mmHg vs. 9.82± 0.41 mmHg,
p = 0.0016, <0.01), and the IOP remained elevated for an
additional period of 2 weeks at significantly higher levels than
those in the NC group at every time point over the entire 2-week
study period (t-test, p= 0.028,<0.05 for each time point). MANF
administration did not alter the IOP (n = 22, p = 0.32, >0.05).
Therefore, the results demonstrated that the microbead injection
resulted in COHT.
MANF Rescues RGC Function In vivo
The function of the RGCs is impaired before death. To assess
the functional changes in the RGCs, PhNR analysis was carried
out (Figures 5B,C). The results showed that the PhNR amplitude
was significantly reduced by approximately 48.52% after 3 days
of COHT (n = 25, p = 0.0039, <0.01), which indicated that
RGC function was significantly impaired in the early stage of
COHT. With sustained COHT over time, the amplitudes of the
PhNR declined further and were reduced by 69.43± 7.23% in the
second week after COHT induction (n= 16, p= 0.0006,<0.001).
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FIGURE 4 | Western blot analysis was performed. The expression levels of cleaved caspase-3, survivin, MANF, and CHOP were determined in the RGCs from
the three different treatment groups: NC group, CoCl2 treatment group, and CoCl2 with MANF treatment group. The bars represent the means ± SD. β-actin was
used as an internal control. (A) and (C) Bands showing the protein expression. (B) and (D) Band density is represented as normalized ratios (β-actin used as
control = 1). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, the hypoxia group compared with the NC group. #p < 0.05, ##p < 0.01, the hypoxia + MANF group compared
with the hypoxia group.
As expected, MANF administration significantly rescued the
amplitudes of the PhNR in the early stage of COHT, which
had recovered by approximately 32.56 ± 5.25% on the third
day (n = 22, p = 0.031, <0.05) and by 40.78 ± 7.11% in the
second week (n= 15, p= 0.008,<0.01). Collectively, these results
demonstrated that MANF effectively attenuated RGC functional
impairment in the early stage of COHT, and the protective effect
in the early stage of COHT was greater than that in the later stage
of COHT (p< 0.05).
MANF Promotes RGC Survival In vivo
To assess whether MANF administration could increase RGC
survival under COHT, RGC loss was assessed by retrograde
FG labeling (Figure 6). The mean RGC density in the eyes
before microbead injection was 2633 ± 422 cells/mm2, and
microbead-induced IOP elevation led to a gradual reduction of
RGC somas over time (no evident differences during the first
3 days, n = 4, p > 0.01). The number of RGCs decreased by
33.98 ± 5.77% during the 1st week (n = 8, p = 0.0066, <0.01)
and by 61.33 ± 8.21% during the 2nd week (n = 8, p = 0.0005,
<0.001), while the number of RGCs increased by 20.33 ± 4.55%
in the 1st week (n= 7, p= 0.041,<0.05) and by 39.77± 6.59% in
the 2nd week (n = 7, p = 0.0078, <0.01) in the rats treated with
MANF after COHT. These results indicated that MANF reduced
the death of the RGCs after COHT and increased the survival rate
of the RGCs.
To further confirm the protective effect of MANF on RGCs
under COHT, the levels of survivin, a protein that inhibits
apoptosis, were measured by immunofluorescence staining and
Western blot analysis (Figure 7). Quantitative estimation showed
that the expression levels of survivin in the ganglion cell
layer (GCL) and inner nuclear layer (INL) were significantly
decreased by 0.42 ± 0.09-fold (immunofluorescence analysis,
n = 6, p = 0.0042, <0.01) vs. 0.59 ± 0.17-fold (Western
blot analysis, n = 6, p = 0.0076, <0.01) after 2 weeks of
COHT. However, the survivin expression levels were markedly
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FIGURE 5 | (A) The mean IOPs of the rats in the NC group (n = 22), COHT group (n = 28), COHT + PBS group (n = 8), and COHT + MANF group (n = 22). IOP was
measured from 0 to 2 weeks after the microbead injections. The data are presented as the means ± standard deviations (SD). (B) The PhNR amplitudes at baseline
(n = 22, 28, and 22), 3 days (n = 14, 25, and 22), and 2 weeks (n = 9, 16, and 15) in the NC group, COHT with MANF group, and COHT without MANF group,
respectively. (C) Quantification of the mean amplitudes of the three groups. The data are expressed as the means ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
increased by 0.89 ± 0.21-fold (Western blot analysis, n = 6,
p = 0.018, <0.05) in the retinas treated with MANF. Together,
these findings strongly suggest that intravitreal delivery of MANF
can promote the survival of RGCs in this model of chronic
glaucoma.
MANF in the Vitreous
Because MANF is a secreted protein and certain amounts of
vitreous proteins originate from the retina (Skeie and Mahajan,
2011), there is a significant possibility that MANF may be
present in the vitreous. To determine whether MANF was present
in the vitreous, the vitreous of human donors was extracted
and used for Western blotting to measure the expression of
MANF. We found that MANF was exactly present in human
vitreous; specifically, a major protein band of the expected
molecular weight, 25 kDa, was clearly identified (Figure 8A).
The protein composition and content of the vitreous may
change under physiological and pathological conditions of
Frontiers in Molecular Neuroscience | www.frontiersin.org 8 March 2017 | Volume 10 | Article 76
fnmol-10-00076 March 15, 2017 Time: 16:5 # 9
Gao et al. Neuroprotective Effects of MANF on RGC
FIGURE 6 | (A) Representative regions of FG-labeled RGCs in the flat-mounted retinas in the NC group and COHT with or without MANF groups after 0 (n = 4), 7
(n = 5, 8, and 7, respectively), and 14 (n = 5, 8, and 7, respectively) days after the microbead injections, and all images were captured at the same magnification.
Scale bar, 100 µm. (B) Quantitation of the FG-labeled RGCs. The data are presented as the means ± SD, ∗∗p < 0.01, ∗∗∗p < 0.001, the COHT group compared
with the NC group. #p < 0.05, ##p < 0.01, the COHT + MANF group compared with the COHT group at the same time point after the microbead injections.
FIGURE 7 | (A) Representative immunohistochemical images of survivin staining (red) in retinas from the three different treatment groups at 2 weeks after the
microbead injections. The NC group (top, n = 8), COHT group (middle, n = 8), and COHT + MANF group (bottom, n = 8). Red indicates survivin staining; blue
indicates DAPI. Scale bar, 50 µm. (B) Quantitative analysis of survivin-positive regions in the retinas from the different treatment groups. (C,D) Western blot analysis
of survivin expression in the three different groups. β-actin was used as an internal control. The level of protein in each group is expressed as the value relative to the
NC group. The data are presented as the means ± SD, ∗p < 0.05, ∗∗p < 0.01.
the retina. With the use of ELISA assay kits, we detected
MANF in all vitreous fluid samples from different retinopathies,
including proliferative diabetic retinopathy (with or without
vitreous hemorrhage), macular holes, and retinal detachment
(Figure 8B). The mean levels of MANF in the vitreous
samples from patients with proliferative diabetic retinopathy
(n = 21) (3.44 ± 1.07 ng/ml) and retinal detachments (n = 16)
(3.43 ± 1.09 ng/ml) were significantly higher than those in
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FIGURE 8 | (A) Western blot analysis of MANF expression in the vitreous of
human donors; a major band at the expected molecular weight (25 kDa) is
apparent. (B) MANF concentrations in the vitreous of patients with MH
(n = 18), PDR (n = 21), and RD (n = 16). The data are presented as the
means ± SD, ∗∗p < 0.01, ∗∗∗p < 0.001. RD, retinal detachment; MH,
macular hole; PDR, proliferative diabetic retinopathy; p-PDR, pure proliferative
diabetic retinopathy without vitreous hemorrhage, PDR + VH, proliferative
diabetic retinopathy with vitreous hemorrhage.
patients with macular holes (n = 18) (1.21 ± 0.28 ng/ml)
(p < 0.001). The MANF levels were clearly lower in the
vitreous samples from patients with pure proliferative diabetic
retinopathy (n = 8) (2.07 ± 0.14 ng/ml) compared with those
from the patients with proliferative diabetic retinopathy with
vitreous hemorrhage (n= 13) (3.77± 0.97 ng/ml) (p< 0.01).
DISCUSSION
There are three important findings in the current study:
(1) MANF was detected in the vitreous humor and highly
expressed in the RGCs. (2) Exogenous MANF protected
the RGCs from hypoxia-induced cell injury and apoptosis
both in vitro and in vivo by preventing ERS-mediated
apoptosis. (3) MANF levels in the vitreous humor were
significantly higher in patients with proliferative diabetic
retinopathy and retinal detachments compared with patients
with macular holes. This is the first study to investigate
the neuroprotective effects of MANF on RGC function and
apoptosis both in vivo and in vitro, and it is the first
study to report that MANF is detectable in human vitreous
humor and exhibits altered expression under pathological
conditions.
Mesencephalic astrocyte-derived neurotrophic factor, with a
molecular weight of 25 kDa, is widely expressed in mammalian
tissues (Lindholm et al., 2008). Increasing evidence indicates
that MANF promotes the survival of dopamine neurons
at least partially by regulating the ER stress response, and
MANF improves motor function more efficiently than other
neurotrophic factors (Voutilainen et al., 2015). New research
in the latest issue of Science suggests that MANF promotes
tissue repair and successful regeneration in the retina (Neves
et al., 2016). In view of these findings, we hypothesized that
MANF may be expressed in the retina and protect the retinal
tissue through particular mechanisms. To test this hypothesis, we
needed to study the expression of MANF in the retinal tissue. Our
results verified that MANF was highly expressed in RGCs, which
provided a good foundation for our further studies.
An in vitro analysis of RGCs is a crucial and nearly
indispensable tool for the study of retinal visual physiology
and pathophysiology associated with various retinopathies
and neuropathies, which cannot easily be realized in animal
models. In addition, hypoxia is an important cause of many
ocular diseases, including glaucoma (Li et al., 2011). Our in
vitro study provided direct evidence of the protective effect
of MANF on hypoxia-induced RGC loss. Moreover, CHOP,
a key player in ER stress-mediated apoptosis (Oyadomari
et al., 2002), and the pro-apoptotic protein cleaved caspase-3
were downregulated by MANF, which suggested that MANF
exerts protective effects on RGCs and prevents ERS-mediated
apoptosis.
The in vitro environment is relatively simple, and it
was unknown whether MANF exerts a similar protective
benefit on RGCs in vivo. To further examine the role
of MANF in the survival of RGCs under pathological
conditions, we used the COHT model, also known as ischemia-
reperfusion, which has been widely used to investigate the
mechanisms of RGC death (Sandalon et al., 2013). There is
compelling evidence that RGC dysfunction occurs earlier and
precedes the loss of RGC somas in glaucoma (Shou et al.,
2003). Therefore, early functional protection is crucial for
slowing the progression of glaucomatous optic neuropathy.
The PhNR, which can be measured by a minimally invasive
electrophysiological technique, has been reported to originate
primarily from the RGCs and their axons (Porciatti, 2015).
It provides a direct, objective assessment of the functional
changes in the RGCs (Wilsey and Fortune, 2016). In the
current study, a significant functional impairment in the
RGCs was identified under COHT, while MANF treatment
rescued the early PhNR deficit after 3 days of COHT, which
indicated that MANF can protect against RGC functional
damage in the early stage of COHT, even though RGC
function was not returned to normal levels. However, with
the progression of COHT, only a small trend of functional
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improvement was found. It is possible that with prolonged
COHT, additional traumatic pathological pathways are activated
such that MANF can no longer confer a sufficient protective
effect. RGC apoptosis increased following the functional damage
after IOP elevation. FG retrograde labeling showed that MANF
effectively inhibited RGC apoptosis without decreasing IOP,
and the early protection capacity was far greater than the
later effects, which is consistent with the results of the
functional assessment. Additionally, these results were further
verified by quantitative analysis of survivin expression levels.
Collectively, we can confirm that MANF plays a protective role
in RGC function and survival under hypoxia both in vitro and
in vivo.
Mesencephalic astrocyte-derived neurotrophic factor is a
secreted protein and is detectable in human serum (Galli et al.,
2016). Thus, we questioned whether MANF is detectable in the
vitreous and whether vitreous MANF levels are associated with
retinopathy. As we expected, MANF was found in the human
vitreous, and MANF levels were elevated under pathological
conditions, such as proliferative diabetic retinopathy and
retinal detachment, compared with macular holes. The MANF
expression levels were clearly lower in the vitreous samples from
patients with pure proliferative diabetic retinopathy compared
with those from patients with proliferative diabetic retinopathy
with vitreous hemorrhage, and this finding may be due to the
mixing of the vitreous with blood, as extremely concentrations
of MANF are present in the serum (Galli et al., 2016). These
data suggest that MANF in the human vitreous humor may be
an interesting protein biomarker for the indirect detection of
retinal disorders, which can provide indirect evidence for retinal
pathology.
The limitations of this study include the small number of
vitreous samples, which may not have been sufficient. A larger
number of samples are needed for future studies. In addition,
we used patients with macular holes as a healthy control group
due to the lack of normal samples. Unfortunately, we also had
no data on whether MANF expression levels are associated with
the progression of retinal diseases or the expression of other
cytokines in the vitreous. Finally, the origins and mechanisms of
increased vitreous MANF have not yet been revealed.
CONCLUSION
This study provides the first direct evidence to date that
MANF is highly expressed in RGCs and that exogenous
MANF can protect RGCs from hypoxia-induced cell injury
and apoptosis in both a rat model of chronic glaucoma
in vivo and hypoxia-induced RGC apoptosis in vitro. The
mechanisms of MANF protection depended on the prevention
of ERS-mediated apoptosis, not decreased IOP. Additionally,
an interesting finding of potential clinical relevance in this
study is that MANF protein can be detected in the vitreous.
Furthermore, patients with proliferative diabetic retinopathy and
retinal detachments showed a significantly higher MANF level
compared with patients with macular holes. Thus, our results
provide important evidence demonstrating that MANF may be
a potential therapeutic protein for the treatment of a range
of retinal pathologies either in the preclinical stage or after
diagnosis to promote the survival of RGCs. Vitreous MANF may
be a promising protein biomarker for the indirect assessment of
retinal disorders, which could also provide indirect evidence of
retinal pathology. Nevertheless, MANF requires further attention
and investigation.
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